Biogen (BIIB) Expected to Announce Quarterly Earnings on Friday

Biogen (NASDAQ:BIIB) is expected to be issuing its Q4 2025 results before the market opens on Friday, February 6th. Analysts expect Biogen to post earnings of $1.72 per share and revenue of $2.2147 billion for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 6, 2026 at 8:30 AM ET.

Biogen Trading Up 4.9%

Shares of Biogen stock opened at $185.45 on Thursday. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $190.20. The business’s fifty day moving average is $176.48 and its two-hundred day moving average is $155.92. The company has a quick ratio of 2.04, a current ratio of 2.72 and a debt-to-equity ratio of 0.35. The firm has a market cap of $27.21 billion, a PE ratio of 16.91, a P/E/G ratio of 1.48 and a beta of 0.16.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 748 shares of Biogen stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $179.30, for a total transaction of $134,116.40. Following the transaction, the insider owned 6,271 shares in the company, valued at approximately $1,124,390.30. The trade was a 10.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.18% of the company’s stock.

Institutional Investors Weigh In On Biogen

Several institutional investors and hedge funds have recently modified their holdings of BIIB. WFA of San Diego LLC purchased a new stake in shares of Biogen during the 2nd quarter valued at about $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in Biogen in the third quarter valued at approximately $54,000. MUFG Securities EMEA plc purchased a new stake in shares of Biogen during the second quarter valued at approximately $54,000. Larson Financial Group LLC raised its stake in shares of Biogen by 23.4% during the third quarter. Larson Financial Group LLC now owns 638 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 121 shares during the period. Finally, CIBC Private Wealth Group LLC lifted its position in shares of Biogen by 8.1% during the third quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 89 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Wells Fargo & Company raised their price target on Biogen from $155.00 to $190.00 and gave the stock an “equal weight” rating in a research note on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Wall Street Zen downgraded shares of Biogen from a “buy” rating to a “hold” rating in a report on Sunday, November 9th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $225.00 price target on shares of Biogen in a research report on Thursday, January 8th. Finally, Oppenheimer lifted their price target on shares of Biogen from $205.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, January 30th. Eleven equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $192.58.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Nature Medicine published pivotal DEVOTE results showing the high‑dose nusinersen regimen produced statistically significant motor and biomarker improvements versus lower dose / untreated comparators; safety was broadly consistent and the regimen is under FDA review with an April 3 PDUFA date — a clear potential revenue and label expansion catalyst for SPINRAZA. Nature Medicine Publishes DEVOTE Results
• Positive Sentiment: RBC Capital issued a buy/outperform view on BIIB, which supports upward price momentum by increasing institutional confidence and may attract more buyers ahead of earnings and the PDUFA decision. Biogen Receives a Buy from RBC Capital
• Neutral Sentiment: Market previews flag Q4 results and guidance as near‑term drivers — MS franchise pressures are a headwind but growth from newer assets (Leqembi, Skyclarys) could help offset declines; earnings delivery will likely drive short‑term volatility. Biogen Reports Q4: Everything You Need To Know Ahead Of Earnings
• Neutral Sentiment: Zacks preview notes new drug dynamics are key heading into Q4 — useful context but not an immediate directional trigger absent surprises in the print or guidance. New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings
• Neutral Sentiment: Bernstein maintained a Hold (market‑perform) with a ~$191 target, signaling mixed near‑term fundamentals but acknowledging optional upside from emerging assets — this keeps analyst sentiment balanced. Biogen: Unexciting Near-Term Fundamentals but Optionality in Emerging Assets
• Negative Sentiment: An insider (Priya Singhal) disclosed a sale of 748 shares (~$134k) on Feb 2; small in size but sometimes viewed as a modest negative signal by some investors. Insider Form 4 — Priya Singhal Sale

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.